Heike Wulff - Publications

Affiliations: 
Chemistry University of California, Davis, Davis, CA 
Area:
Organic Chemistry, Medicine and Surgery

113 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Jin LW, Lucente JD, Nguyen HM, Singh V, Singh L, Chavez M, Bushong T, Wulff H, Maezawa I. Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease. Annals of Clinical and Translational Neurology. 6: 723-738. PMID 31019997 DOI: 10.1002/acn3.754  0.4
2018 Di Lucente J, Nguyen HM, Wulff H, Jin LW, Maezawa I. The voltage-gated potassium channel Kv1.3 is required for microglial pro-inflammatory activation in vivo. Glia. PMID 30043400 DOI: 10.1002/glia.23457  0.4
2018 Slavi N, Toychiev AH, Kosmidis S, Ackert J, Bloomfield SA, Wulff H, Viswanathan S, Lampe PD, Srinivas M. Suppression of connexin 43 phosphorylation promotes astrocyte survival and vascular regeneration in proliferative retinopathy. Proceedings of the National Academy of Sciences of the United States of America. PMID 29891713 DOI: 10.1073/pnas.1803907115  0.32
2018 Chen YJ, Nguyen HM, Maezawa I, Jin LW, Wulff H. Inhibition of the potassium channel Kv1.3 reduces infarction and inflammation in ischemic stroke. Annals of Clinical and Translational Neurology. 5: 147-161. PMID 29468176 DOI: 10.1002/acn3.513  0.4
2017 Maezawa I, Nguyen HM, Di Lucente J, Jenkins DP, Singh V, Hilt S, Kim K, Rangaraju S, Levey AI, Wulff H, Jin LW. Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept. Brain : a Journal of Neurology. PMID 29272333 DOI: 10.1093/brain/awx346  0.4
2017 Nguyen HM, Singh V, Pressly B, Jenkins DP, Wulff H, Yarov-Yarovoy V. Structural Insights into the Atomistic Mechanisms of Action of Small Molecule Inhibitors Targeting the KCa3.1 Channel Pore. Molecular Pharmacology. PMID 28126850 DOI: 10.1124/mol.116.108068  0.32
2016 Hilt S, Tang T, Walton JH, Budamagunta M, Maezawa I, Kálai T, Hideg K, Singh V, Wulff H, Gong Q, Jin LW, Louie A, Voss JC. A Metal-Free Method for Producing MRI Contrast at Amyloid-β. Journal of Alzheimer's Disease : Jad. PMID 27911291 DOI: 10.3233/JAD-160279  0.4
2016 Nguyen HM, Grössinger EM, Horiuchi M, Davis KW, Jin LW, Maezawa I, Wulff H. Differential Kv1.3, KCa3.1, and Kir2.1 expression in "classically" and "alternatively" activated microglia. Glia. PMID 27696527 DOI: 10.1002/glia.23078  0.4
2016 Pessah IN, Rogawski MA, Tancredi DJ, Wulff H, Zolkowska D, Bruun DA, Hammock BD, Lein PJ. Models to identify treatments for the acute and persistent effects of seizure-inducing chemical threat agents. Annals of the New York Academy of Sciences. PMID 27467073 DOI: 10.1111/nyas.13137  0.56
2016 Glaser N, Little C, Lo W, Cohen M, Tancredi D, Wulff H, O'Donnell M. Treatment with the KCa3.1 inhibitor TRAM-34 during diabetic ketoacidosis reduces inflammatory changes in the brain. Pediatric Diabetes. PMID 27174668 DOI: 10.1111/pedi.12396  0.56
2016 D'Alessandro G, Grimaldi A, Chece G, Porzia A, Esposito V, Santoro A, Salvati M, Mainiero F, Ragozzino D, Di Angelantonio S, Wulff H, Catalano M, Limatola C. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment. Oncotarget. PMID 27096953 DOI: 10.18632/oncotarget.8761  0.56
2016 Oliván-Viguera A, Valero MS, Pinilla E, Amor S, García-Villalón ÁL, Coleman N, Laría C, Calvín-Tienza V, García-Otín ÁL, Fernández-Fernández JM, Murillo MD, Gálvez JA, Díaz-de-Villegas MD, Badorrey R, Simonsen U, ... ... Wulff H, et al. Vascular reactivity profile of novel KC a 3.1-selective positive-gating modulators in the coronary vascular bed. Basic & Clinical Pharmacology & Toxicology. PMID 26821335 DOI: 10.1111/bcpt.12560  0.56
2016 Grimaldi A, D'Alessandro G, Golia MT, Grössinger EM, Di Angelantonio S, Ragozzino D, Santoro A, Esposito V, Wulff H, Catalano M, Limatola C. KCa3.1 inhibition switches the phenotype of glioma-infiltrating microglia/macrophages Cell Death and Disease. 7. DOI: 10.1038/cddis.2016.73  0.56
2016 Köhler R, Oliván-Viguera A, Wulff H. Endothelial Small- and Intermediate-Conductance K Channels and Endothelium-Dependent Hyperpolarization as Drug Targets in Cardiovascular Disease Advances in Pharmacology. DOI: 10.1016/bs.apha.2016.04.002  0.56
2015 Chen YJ, Nguyen HM, Maezawa I, Grössinger EM, Garing AL, Köhler R, Jin LW, Wulff H. The potassium channel KCa3.1 constitutes a pharmacological target for neuroinflammation associated with ischemia/reperfusion stroke. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. PMID 26661208 DOI: 10.1177/0271678X15611434  0.4
2015 Wulff H, Christophersen P. Recent developments in ion channel pharmacology. Channels (Austin, Tex.). 9: 335. PMID 26646476 DOI: 10.1080/19336950.2015.1077650  0.56
2015 Hong L, Singh V, Wulff H, Tombola F. Interrogation of the intersubunit interface of the open Hv1 proton channel with a probe of allosteric coupling. Scientific Reports. 5: 14077. PMID 26365828 DOI: 10.1038/srep14077  0.56
2015 Dell'Orco JM, Wasserman AH, Chopra R, Ingram MA, Hu YS, Singh V, Wulff H, Opal P, Orr HT, Shakkottai VG. Neuronal Atrophy Early in Degenerative Ataxia Is a Compensatory Mechanism to Regulate Membrane Excitability. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 11292-307. PMID 26269637 DOI: 10.1523/JNEUROSCI.1357-15.2015  0.56
2015 Mishra R, Mitchell JR, Gibbons-Kroeker C, Wulff H, Belenkie I, Tyberg JV, Braun AP. A Pharmacologic Activator of Endothelial KCa Channels Increases Systemic Conductance and Reduces Arterial Pressure in an Anesthetized Pig Model. Vascular Pharmacology. PMID 26239885 DOI: 10.1016/j.vph.2015.07.016  0.56
2015 Christophersen P, Wulff H. Pharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (KCa2.x and KCa3.1). Channels (Austin, Tex.). 9: 336-43. PMID 26217968 DOI: 10.1080/19336950.2015.1071748  0.56
2015 Feske S, Wulff H, Skolnik EY. Ion channels in innate and adaptive immunity. Annual Review of Immunology. 33: 291-353. PMID 25861976 DOI: 10.1146/annurev-immunol-032414-112212  0.56
2015 Roach KM, Feghali-Bostwick C, Wulff H, Amrani Y, Bradding P. Human lung myofibroblast TGFβ1-dependent Smad2/3 signalling is Ca(2+)-dependent and regulated by KCa3.1 K(+) channels. Fibrogenesis & Tissue Repair. 8: 5. PMID 25829947 DOI: 10.1186/s13069-015-0022-0  0.56
2015 Mishra RC, Wulff H, Hill MA, Braun AP. Inhibition of Myogenic Tone in Rat Cremaster and Cerebral Arteries by SKA-31, an Activator of Endothelial KCa2.3 and KCa3.1 Channels. Journal of Cardiovascular Pharmacology. 66: 118-27. PMID 25815673 DOI: 10.1097/FJC.0000000000000252  0.56
2015 Jin LW, Horiuchi M, Wulff H, Liu XB, Cortopassi GA, Erickson JD, Maezawa I. Dysregulation of glutamine transporter SNAT1 in Rett syndrome microglia: a mechanism for mitochondrial dysfunction and neurotoxicity. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 2516-29. PMID 25673846 DOI: 10.1523/JNEUROSCI.2778-14.2015  0.56
2015 Cao Z, Zou X, Cui Y, Hulsizer S, Lein PJ, Wulff H, Pessah IN. Rapid throughput analysis demonstrates that chemicals with distinct seizurogenic mechanisms differentially alter Ca2+ dynamics in networks formed by hippocampal neurons in culture. Molecular Pharmacology. 87: 595-605. PMID 25583085 DOI: 10.1124/mol.114.096701  0.56
2015 Chen YJ, Wallace BK, Yuen N, Jenkins DP, Wulff H, O'Donnell ME. Blood-brain barrier KCa3.1 channels: evidence for a role in brain Na uptake and edema in ischemic stroke. Stroke; a Journal of Cerebral Circulation. 46: 237-44. PMID 25477223 DOI: 10.1161/STROKEAHA.114.007445  0.56
2015 Oliván-Viguera A, Valero MS, Coleman N, Brown BM, Laría C, Murillo MD, Gálvez JA, Díaz-de-Villegas MD, Wulff H, Badorrey R, Köhler R. A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo. Molecular Pharmacology. 87: 338-48. PMID 25468883 DOI: 10.1124/mol.114.095745  0.56
2015 Waeckel L, Badier-Commander C, Damery T, Köhler R, Sansilvestri-Morel P, Simonet S, Vayssettes-Courchay C, Wulff H, Félétou M. Vascular dysfunctions in the isolated aorta of double-transgenic hypertensive mice developing aortic aneurysm. PflüGers Archiv : European Journal of Physiology. 467: 1945-63. PMID 25385304 DOI: 10.1007/s00424-014-1644-6  0.56
2015 Coleman N, Nguyen HM, Cao Z, Brown BM, Jenkins DP, Zolkowska D, Chen YJ, Tanaka BS, Goldin AL, Rogawski MA, Pessah IN, Wulff H. The riluzole derivative 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a mixed KCa2 activator and NaV blocker, is a potent novel anticonvulsant. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 12: 234-49. PMID 25256961 DOI: 10.1007/s13311-014-0305-y  0.56
2015 Waeckel L, Bertin F, Clavreul N, Damery T, Köhler R, Paysant J, Sansilvestri-Morel P, Simonet S, Vayssettes-Courchay C, Wulff H, Verbeuren TJ, Félétou M. Preserved regulation of renal perfusion pressure by small and intermediate conductance KCa channels in hypertensive mice with or without renal failure. PflüGers Archiv : European Journal of Physiology. 467: 817-31. PMID 24903240 DOI: 10.1007/s00424-014-1542-y  0.56
2014 Roach KM, Wulff H, Feghali-Bostwick C, Amrani Y, Bradding P. Increased constitutive αSMA and Smad2/3 expression in idiopathic pulmonary fibrosis myofibroblasts is KCa3.1-dependent. Respiratory Research. 15: 155. PMID 25476248 DOI: 10.1186/s12931-014-0155-5  0.56
2014 Kundu-Raychaudhuri S, Chen YJ, Wulff H, Raychaudhuri SP. Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model. Journal of Autoimmunity. 55: 63-72. PMID 25175978 DOI: 10.1016/j.jaut.2014.07.003  0.56
2014 Lee KS, Liu JY, Wagner KM, Pakhomova S, Dong H, Morisseau C, Fu SH, Yang J, Wang P, Ulu A, Mate CA, Nguyen LV, Hwang SH, Edin ML, Mara AA, ... Wulff H, et al. Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. Journal of Medicinal Chemistry. 57: 7016-30. PMID 25079952 DOI: 10.1021/jm500694p  0.56
2014 Coleman N, Brown BM, Oliván-Viguera A, Singh V, Olmstead MM, Valero MS, Köhler R, Wulff H. New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1. Molecular Pharmacology. 86: 342-57. PMID 24958817 DOI: 10.1124/mol.114.093286  0.56
2014 Chhabra S, Chang SC, Nguyen HM, Huq R, Tanner MR, Londono LM, Estrada R, Dhawan V, Chauhan S, Upadhyay SK, Gindin M, Hotez PJ, Valenzuela JG, Mohanty B, Swarbrick JD, ... Wulff H, et al. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 28: 3952-64. PMID 24891519 DOI: 10.1096/fj.14-251967  0.56
2014 Koch Hansen L, Sevelsted-Møller L, Rabjerg M, Larsen D, Hansen TP, Klinge L, Wulff H, Knudsen T, Kjeldsen J, Köhler R. Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis. Journal of Crohn's & Colitis. 8: 1378-91. PMID 24793818 DOI: 10.1016/j.crohns.2014.04.003  0.56
2014 Mishra RC, Wulff H, Cole WC, Braun AP. A pharmacologic activator of endothelial KCa channels enhances coronary flow in the hearts of type 2 diabetic rats. Journal of Molecular and Cellular Cardiology. 72: 364-73. PMID 24787473 DOI: 10.1016/j.yjmcc.2014.04.013  0.56
2014 Luna-Cancalon K, Sikora KM, Pappas SS, Singh V, Wulff H, Paulson HL, Burmeister M, Shakkottai VG. Alterations in cerebellar physiology are associated with a stiff-legged gait in Atcay(ji-hes) mice. Neurobiology of Disease. 67: 140-8. PMID 24727095 DOI: 10.1016/j.nbd.2014.03.020  0.56
2014 Cao Z, Cui Y, Nguyen HM, Jenkins DP, Wulff H, Pessah IN. Nanomolar bifenthrin alters synchronous Ca2+ oscillations and cortical neuron development independent of sodium channel activity. Molecular Pharmacology. 85: 630-9. PMID 24482397 DOI: 10.1124/mol.113.090076  0.56
2013 Roach KM, Roach KM, Duffy SM, Coward W, Feghali-Bostwick C, Wulff H, Bradding P. The K+ channel KCa3.1 as a novel target for idiopathic pulmonary fibrosis. Plos One. 8: e85244. PMID 24392001 DOI: 10.1371/journal.pone.0085244  0.56
2013 Jenkins DP, Yu W, Brown BM, Løjkner LD, Wulff H. Development of a QPatch automated electrophysiology assay for identifying KCa3.1 inhibitors and activators. Assay and Drug Development Technologies. 11: 551-60. PMID 24351043 DOI: 10.1089/adt.2013.543  0.56
2013 Chen YJ, Lam J, Gregory CR, Schrepfer S, Wulff H. The Ca²⁺-activated K⁺ channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy. Plos One. 8: e81006. PMID 24312257 DOI: 10.1371/journal.pone.0081006  0.56
2013 Koshy S, Wu D, Hu X, Tajhya RB, Huq R, Khan FS, Pennington MW, Wulff H, Yotnda P, Beeton C. Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes. Plos One. 8: e76740. PMID 24146918 DOI: 10.1371/journal.pone.0076740  0.56
2013 D'Alessandro G, Catalano M, Sciaccaluga M, Chece G, Cipriani R, Rosito M, Grimaldi A, Lauro C, Cantore G, Santoro A, Fioretti B, Franciolini F, Wulff H, Limatola C. KCa3.1 channels are involved in the infiltrative behavior of glioblastoma in vivo. Cell Death & Disease. 4: e773. PMID 23949222 DOI: 10.1038/cddis.2013.279  0.56
2013 Lam J, Coleman N, Garing AL, Wulff H. The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases. Expert Opinion On Therapeutic Targets. 17: 1203-20. PMID 23883298 DOI: 10.1517/14728222.2013.823161  0.56
2013 Wulff H, Yarov-Yarovoy V. Channels: Sticking to nooks and crannies. Nature Chemical Biology. 9: 473-4. PMID 23868316 DOI: 10.1038/nchembio.1292  0.56
2013 Van Der Velden J, Sum G, Barker D, Koumoundouros E, Barcham G, Wulff H, Castle N, Bradding P, Snibson K. K(Ca)3.1 channel-blockade attenuates airway pathophysiology in a sheep model of chronic asthma. Plos One. 8: e66886. PMID 23826167 DOI: 10.1371/journal.pone.0066886  0.56
2013 Radtke J, Schmidt K, Wulff H, Köhler R, de Wit C. Activation of KCa3.1 by SKA-31 induces arteriolar dilatation and lowers blood pressure in normo- and hypertensive connexin40-deficient mice. British Journal of Pharmacology. 170: 293-303. PMID 23734697 DOI: 10.1111/bph.12267  0.56
2013 Bi D, Toyama K, Lemaître V, Takai J, Fan F, Jenkins DP, Wulff H, Gutterman DD, Park F, Miura H. The intermediate conductance calcium-activated potassium channel KCa3.1 regulates vascular smooth muscle cell proliferation via controlling calcium-dependent signaling. The Journal of Biological Chemistry. 288: 15843-53. PMID 23609438 DOI: 10.1074/jbc.M112.427187  0.56
2013 Bradding P, Wulff H. Ion channels. Thorax. 68: 974-7. PMID 23564342 DOI: 10.1136/thoraxjnl-2012-202786  0.56
2013 Oliván-Viguera A, Valero MS, Murillo MD, Wulff H, García-Otín AL, Arbonés-Mainar JM, Köhler R. Novel phenolic inhibitors of small/intermediate-conductance Ca²⁺-activated K⁺ channels, KCa3.1 and KCa2.3. Plos One. 8: e58614. PMID 23516517 DOI: 10.1371/journal.pone.0058614  0.56
2013 Hua X, Deuse T, Chen YJ, Wulff H, Stubbendorff M, Köhler R, Miura H, Länger F, Reichenspurner H, Robbins RC, Schrepfer S. The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease. Transplantation. 95: 285-92. PMID 23325003 DOI: 10.1097/TP.0b013e318275a2f4  0.56
2013 Girodet PO, Ozier A, Carvalho G, Ilina O, Ousova O, Gadeau AP, Begueret H, Wulff H, Marthan R, Bradding P, Berger P. Ca(2+)-activated K(+) channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model. American Journal of Respiratory Cell and Molecular Biology. 48: 212-9. PMID 23204391 DOI: 10.1165/rcmb.2012-0103OC  0.56
2013 Mishra RC, Belke D, Wulff H, Braun AP. SKA-31, a novel activator of SK(Ca) and IK(Ca) channels, increases coronary flow in male and female rat hearts. Cardiovascular Research. 97: 339-48. PMID 23118129 DOI: 10.1093/cvr/cvs326  0.56
2013 Wulff H, Köhler R. Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets. Journal of Cardiovascular Pharmacology. 61: 102-12. PMID 23107876 DOI: 10.1097/FJC.0b013e318279ba20  0.56
2013 Strøbæk D, Brown DT, Jenkins DP, Chen YJ, Coleman N, Ando Y, Chiu P, Jørgensen S, Demnitz J, Wulff H, Christophersen P. NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease. British Journal of Pharmacology. 168: 432-44. PMID 22891655 DOI: 10.1111/j.1476-5381.2012.02143.x  0.56
2012 Jin BE, Wulff H, Widdicombe JH, Zheng J, Bers DM, Puglisi JL. A simple device to illustrate the Einthoven triangle. Advances in Physiology Education. 36: 319-24. PMID 23209014 DOI: 10.1152/advan.00029.2012  0.56
2012 Nguyen W, Howard BL, Jenkins DP, Wulff H, Thompson PE, Manallack DT. Structure-activity relationship exploration of Kv1.3 blockers based on diphenoxylate. Bioorganic & Medicinal Chemistry Letters. 22: 7106-9. PMID 23084278 DOI: 10.1016/j.bmcl.2012.09.080  0.56
2012 Lambertsen KL, Gramsbergen JB, Sivasaravanaparan M, Ditzel N, Sevelsted-Møller LM, Oliván-Viguera A, Rabjerg M, Wulff H, Köhler R. Genetic KCa3.1-deficiency produces locomotor hyperactivity and alterations in cerebral monoamine levels. Plos One. 7: e47744. PMID 23077667 DOI: 10.1371/journal.pone.0047744  0.56
2012 Bodendiek SB, Rubinos C, Trelles MP, Coleman N, Jenkins DP, Wulff H, Srinivas M. Triarylmethanes, a new class of cx50 inhibitors. Frontiers in Pharmacology. 3: 106. PMID 22685432 DOI: 10.3389/fphar.2012.00106  0.56
2012 Maezawa I, Jenkins DP, Jin BE, Wulff H. Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease. International Journal of Alzheimer's Disease. 2012: 868972. PMID 22675649 DOI: 10.1155/2012/868972  0.56
2012 Vandendriessche T, Kopljar I, Jenkins DP, Diego-Garcia E, Abdel-Mottaleb Y, Vermassen E, Clynen E, Schoofs L, Wulff H, Snyders D, Tytgat J. Purification, molecular cloning and functional characterization of HelaTx1 (Heterometrus laoticus): the first member of a new κ-KTX subfamily. Biochemical Pharmacology. 83: 1307-17. PMID 22305749 DOI: 10.1016/j.bcp.2012.01.021  0.56
2012 Chi V, Pennington MW, Norton RS, Tarcha EJ, Londono LM, Sims-Fahey B, Upadhyay SK, Lakey JT, Iadonato S, Wulff H, Beeton C, Chandy KG. Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon : Official Journal of the International Society On Toxinology. 59: 529-46. PMID 21867724 DOI: 10.1016/j.toxicon.2011.07.016  0.56
2012 Damkjaer M, Nielsen G, Bodendiek S, Staehr M, Gramsbergen JB, de Wit C, Jensen BL, Simonsen U, Bie P, Wulff H, Köhler R. Pharmacological activation of KCa3.1/KCa2.3 channels produces endothelial hyperpolarization and lowers blood pressure in conscious dogs. British Journal of Pharmacology. 165: 223-34. PMID 21699504 DOI: 10.1111/j.1476-5381.2011.01546.x  0.56
2011 Maezawa I, Calafiore M, Wulff H, Jin LW. Does microglial dysfunction play a role in autism and Rett syndrome? Neuron Glia Biology. 7: 85-97. PMID 22717189 DOI: 10.1017/S1740925X1200004X  0.56
2011 Lam J, Wulff H. The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression. Drug Development Research. 72: 573-584. PMID 22241939 DOI: 10.1002/ddr.20467  0.56
2011 Shakkottai VG, do Carmo Costa M, Dell'Orco JM, Sankaranarayanan A, Wulff H, Paulson HL. Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 13002-14. PMID 21900579 DOI: 10.1523/JNEUROSCI.2789-11.2011  0.56
2011 Chen YJ, Raman G, Bodendiek S, O'Donnell ME, Wulff H. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 31: 2363-74. PMID 21750563 DOI: 10.1038/jcbfm.2011.101  0.56
2011 Jenkins DP, Strøbæk D, Hougaard C, Jensen ML, Hummel R, Sørensen US, Christophersen P, Wulff H. Negative gating modulation by (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) depends on residues in the inner pore vestibule: pharmacological evidence of deep-pore gating of K(Ca)2 channels. Molecular Pharmacology. 79: 899-909. PMID 21363929 DOI: 10.1124/mol.110.069807  0.56
2011 Hasenau AL, Nielsen G, Morisseau C, Hammock BD, Wulff H, Köhler R. Improvement of endothelium-dependent vasodilations by SKA-31 and SKA-20, activators of small- and intermediate-conductance Ca 2+-activated K +-channels Acta Physiologica. 203: 117-126. PMID 21362152 DOI: 10.1111/j.1748-1716.2010.02240.x  0.56
2011 Hao B, Chen ZW, Zhou XJ, Zimin PI, Miljanich GP, Wulff H, Wang YX. Identification of phase-I metabolites and chronic toxicity study of the Kv1.3 blocker PAP-1 (5-(4-phenoxybutoxy)psoralen) in the rat. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 41: 198-211. PMID 21070145 DOI: 10.3109/00498254.2010.532886  0.56
2011 Maezawa I, Zimin PI, Wulff H, Jin LW. Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. The Journal of Biological Chemistry. 286: 3693-706. PMID 20971854 DOI: 10.1074/jbc.M110.135244  0.56
2010 Wulff H, Castle NA. Therapeutic potential of KCa3.1 blockers: recent advances and promising trends. Expert Review of Clinical Pharmacology. 3: 385-96. PMID 22111618 DOI: 10.1586/ecp.10.11  0.56
2010 Wulff H. Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840. Expert Opinion On Therapeutic Patents. 20: 1759-65. PMID 20954790 DOI: 10.1517/13543776.2010.528392  0.56
2010 Nguyen W, Howard BL, Neale DS, Thompson PE, White PJ, Wulff H, Manallack DT. Use of kv1.3 blockers for inflammatory skin conditions Current Medicinal Chemistry. 17: 2882-2896. PMID 20858170 DOI: 10.2174/092986710792065072  0.56
2010 Zimin PI, Garic B, Bodendiek SB, Mahieux C, Wulff H, Zhorov BS. Potassium channel block by a tripartite complex of two cationophilic ligands and a potassium ion. Molecular Pharmacology. 78: 588-99. PMID 20601455 DOI: 10.1124/mol.110.064014  0.56
2010 Di L, Srivastava S, Zhdanova O, Ding Y, Li Z, Wulff H, Lafaille M, Skolnik EY. Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis. Proceedings of the National Academy of Sciences of the United States of America. 107: 1541-6. PMID 20080610 DOI: 10.1073/pnas.0910133107  0.56
2010 Köhler R, Kaistha BP, Wulff H. Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease. Expert Opinion On Therapeutic Targets. 14: 143-55. PMID 20055714 DOI: 10.1517/14728220903540257  0.56
2010 Al-Ghananeem AM, Abbassi M, Shrestha S, Raman G, Wulff H, Pereira L, Ansari A. Formulation-based approach to support early drug discovery and development efforts: a case study with enteric microencapsulation dosage form development for a triarylmethane derivative TRAM-34; a novel potential immunosuppressant. Drug Development and Industrial Pharmacy. 36: 563-9. PMID 19929567 DOI: 10.3109/03639040903329554  0.56
2009 Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nature Reviews. Drug Discovery. 8: 982-1001. PMID 19949402 DOI: 10.1038/nrd2983  0.56
2009 Grgic I, Wulff H, Eichler I, Flothmann C, Köhler R, Hoyer J. Blockade of T-Lymphocyte KCa3.1 and Kv1.3 Channels as Novel Immunosuppression Strategy to Prevent Kidney Allograft Rejection Transplantation Proceedings. 41: 2601-2606. PMID 19715983 DOI: 10.1016/j.transproceed.2009.06.025  0.56
2009 Grgic I, Kiss E, Kaistha BP, Busch C, Kloss M, Sautter J, Müller A, Kaistha A, Schmidt C, Raman G, Wulff H, Strutz F, Gröne HJ, Köhler R, Hoyer J. Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proceedings of the National Academy of Sciences of the United States of America. 106: 14518-23. PMID 19706538 DOI: 10.1073/pnas.0903458106  0.56
2009 Bradding P, Wulff H. The K+ channels K(Ca)3.1 and K(v)1.3 as novel targets for asthma therapy. British Journal of Pharmacology. 157: 1330-9. PMID 19681865 DOI: 10.1111/j.1476-5381.2009.00362.x  0.56
2009 Srivastava S, Di L, Zhdanova O, Li Z, Vardhana S, Wan Q, Yan Y, Varma R, Backer J, Wulff H, Dustin ML, Skolnik EY. The class II phosphatidylinositol 3 kinase C2beta is required for the activation of the K+ channel KCa3.1 and CD4 T-cells. Molecular Biology of the Cell. 20: 3783-91. PMID 19587117 DOI: 10.1091/mbc.E09-05-0390  0.56
2009 Brähler S, Kaistha A, Schmidt VJ, Wölfle SE, Busch C, Kaistha BP, Kacik M, Hasenau AL, Grgic I, Si H, Bond CT, Adelman JP, Wulff H, de Wit C, Hoyer J, et al. Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation. 119: 2323-32. PMID 19380617 DOI: 10.1161/CIRCULATIONAHA.108.846634  0.56
2009 Bodendiek SB, Mahieux C, Hänsel W, Wulff H. 4-Phenoxybutoxy-substituted heterocycles--a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3. European Journal of Medicinal Chemistry. 44: 1838-52. PMID 19056148 DOI: 10.1016/j.ejmech.2008.10.033  0.56
2009 Sankaranarayanan A, Raman G, Busch C, Schultz T, Zimin PI, Hoyer J, Köhler R, Wulff H. Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Molecular Pharmacology. 75: 281-95. PMID 18955585 DOI: 10.1124/mol.108.051425  0.56
2008 Srivastava S, Zhdanova O, Di L, Li Z, Albaqumi M, Wulff H, Skolnik EY. Protein histidine phosphatase 1 negatively regulates CD4 T cells by inhibiting the K+ channel KCa3.1. Proceedings of the National Academy of Sciences of the United States of America. 105: 14442-6. PMID 18796614 DOI: 10.1073/pnas.0803678105  0.56
2008 Toyama K, Wulff H, Chandy KG, Azam P, Raman G, Saito T, Fujiwara Y, Mattson DL, Das S, Melvin JE, Pratt PF, Hatoum OA, Gutterman DD, Harder DR, Miura H. The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. The Journal of Clinical Investigation. 118: 3025-37. PMID 18688283 DOI: 10.1172/JCI30836  0.56
2008 Wulff H. New light on the "old" chloride channel blocker DIDS. Acs Chemical Biology. 3: 399-401. PMID 18642798 DOI: 10.1021/cb800140m  0.56
2008 Albaqumi M, Srivastava S, Li Z, Zhdnova O, Wulff H, Itani O, Wallace DP, Skolnik EY. KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease. Kidney International. 74: 740-9. PMID 18547995 DOI: 10.1038/ki.2008.246  0.56
2008 Wulff H, Zhorov BS. K+ channel modulators for the treatment of neurological disorders and autoimmune diseases. Chemical Reviews. 108: 1744-73. PMID 18476673 DOI: 10.1021/cr078234p  0.56
2008 Tharp DL, Wamhoff BR, Wulff H, Raman G, Cheong A, Bowles DK. Local delivery of the K Ca3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis Arteriosclerosis, Thrombosis, and Vascular Biology. 28: 1084-1089. PMID 18309114 DOI: 10.1161/ATVBAHA.107.155796  0.56
2007 Pereira LE, Villinger F, Wulff H, Sankaranarayanan A, Raman G, Ansari AA. Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques Experimental Biology and Medicine. 232: 1338-1354. PMID 17959847 DOI: 10.3181/0705-RM-148  0.56
2007 Wulff H, Pennington M. Targeting effector memory T-cells with Kv1.3 blockers. Current Opinion in Drug Discovery & Development. 10: 438-45. PMID 17659485  0.56
2007 Wulff H, Kolski-Andreaco A, Sankaranarayanan A, Sabatier JM, Shakkottai V. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications Current Medicinal Chemistry. 14: 1437-1457. PMID 17584055 DOI: 10.2174/092986707780831186  0.56
2007 Azam P, Sankaranarayanan A, Homerick D, Griffey S, Wulff H. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. The Journal of Investigative Dermatology. 127: 1419-29. PMID 17273162 DOI: 10.1038/sj.jid.5700717  0.56
2007 Moritoki Y, Lian ZX, Wulff H, Yang GX, Chuang YH, Lan RY, Ueno Y, Ansari AA, Coppel RL, Mackay IR, Gershwin ME. AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. Hepatology (Baltimore, Md.). 45: 314-22. PMID 17256753 DOI: 10.1002/hep.21522  0.56
2006 Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, LeeHealey CJ, S Andrews B, Sankaranarayanan A, Homerick D, et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proceedings of the National Academy of Sciences of the United States of America. 103: 17414-9. PMID 17088564 DOI: 10.1073/pnas.0605136103  0.56
2006 Harvey AJ, Baell JB, Toovey N, Homerick D, Wulff H. A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone. Journal of Medicinal Chemistry. 49: 1433-41. PMID 16480279 DOI: 10.1021/jm050839v  0.56
2006 Mouhat S, Teodorescu G, Homerick D, Visan V, Wulff H, Wu Y, Grissmer S, Darbon H, De Waard M, Sabatier JM. Pharmacological profiling of Orthochirus scrobiculosus toxin 1 analogs with a trimmed N-terminal domain. Molecular Pharmacology. 69: 354-62. PMID 16234482 DOI: 10.1124/mol.105.017210  0.56
2005 Wei AD, Gutman GA, Aldrich R, Chandy KG, Grissmer S, Wulff H. International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels Pharmacological Reviews. 57: 463-472. PMID 16382103 DOI: 10.1124/pr.57.4.9  0.56
2005 Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hänsel W, Wulff H. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Molecular Pharmacology. 68: 1254-70. PMID 16099841 DOI: 10.1124/mol.105.015669  0.56
2005 Rus H, Pardo CA, Hu L, Darrah E, Cudrici C, Niculescu T, Niculescu F, Mullen KM, Allie R, Guo L, Wulff H, Beeton C, Judge SI, Kerr DA, Knaus HG, et al. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proceedings of the National Academy of Sciences of the United States of America. 102: 11094-9. PMID 16043714 DOI: 10.1073/pnas.0501770102  0.56
2005 Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, Khaytin I, Calabresi PA, Chen CY, Gutman GA, Chandy KG. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Molecular Pharmacology. 67: 1369-81. PMID 15665253 DOI: 10.1124/mol.104.008193  0.56
2005 Mouhat S, Visan V, Ananthakrishnan S, Wulff H, Andreotti N, Grissmer S, Darbon H, De Waard M, Sabatier JM. K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom. The Biochemical Journal. 385: 95-104. PMID 15588251 DOI: 10.1042/BJ20041379  0.56
2004 Norton RS, Pennington MW, Wulff H. Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases. Current Medicinal Chemistry. 11: 3041-52. PMID 15578998  0.56
2004 Wulff H, Knaus HG, Pennington M, Chandy KG. K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. Journal of Immunology (Baltimore, Md. : 1950). 173: 776-86. PMID 15240664  0.56
2004 Vennekamp J, Wulff H, Beeton C, Calabresi PA, Grissmer S, Hänsel W, Chandy KG. Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Molecular Pharmacology. 65: 1364-74. PMID 15155830 DOI: 10.1124/mol.65.6.1364  0.56
2004 Baell JB, Gable RW, Harvey AJ, Toovey N, Herzog T, Hänsel W, Wulff H. Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity. Journal of Medicinal Chemistry. 47: 2326-36. PMID 15084131 DOI: 10.1021/jm030523s  0.56
2004 Mouhat S, Mosbah A, Visan V, Wulff H, Delepierre M, Darbon H, Grissmer S, De Waard M, Sabatier JM. The 'functional' dyad of scorpion toxin Pi1 is not itself a prerequisite for toxin binding to the voltage-gated Kv1.2 potassium channels. The Biochemical Journal. 377: 25-36. PMID 12962541 DOI: 10.1042/BJ20030115  0.56
2003 Gutman GA, Chandy KG, Adelman JP, Aiyar J, Bayliss DA, Clapham DE, Covarriubias M, Desir GV, Furuichi K, Ganetzky B, Garcia ML, Grissmer S, Jan LY, Karschin A, Kim D, ... ... Wulff H, et al. International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacological Reviews. 55: 583-6. PMID 14657415 DOI: 10.1124/pr.55.4.9  0.56
2002 Ayabe T, Wulff H, Darmoul D, Cahalan MD, Chandy KG, Ouellette AJ. Modulation of mouse Paneth cell alpha-defensin secretion by mIKCa1, a Ca2+-activated, intermediate conductance potassium channel. The Journal of Biological Chemistry. 277: 3793-800. PMID 11724775 DOI: 10.1074/jbc.M107507200  0.56
Show low-probability matches.